Gilead received $6.5 billion from the National Institutes of Health to develop remdesivir. During its first year, the drug brought in $2.3 billion in revenue for Gilead.
#Remdesivir #Gilead
#Remdesivir #Gilead
https://www.inquirer.com
Effective treatments for COVID-19 are tough to develop, but this pill is raising hopes
The arsenal of antiviral drugs is small compared to the armory of antibiotics. There are scientific reasons.